Tianjin CanSino Biologics
185 South Avenue
TEDA West District
Tianjin
300457
China
Tel: 022-25616001-104
Fax: 022-25616006
Website: http://www.cansinotech.com
Email: info@cansinotech.com
About Tianjin CanSino Biologics
Tianjin CanSino Biotech Inc. is an emerging biotechnology company dedicated to vaccine research, development and commercialization. We seek to address the pressing unmet medical needs by developing and marketing leading-edge, high quality vaccines for China and other emerging markets at affordable prices.YEAR FOUNDED:
2009
LEADERSHIP:
Founders: Xuefeng Yu, Tao Zhu, Helen (Huihua) Mao, Dongxu Qiu
Founder and CEO: Xuefeng Yu
Founder and CSO: Tao Zhu
CLINICAL TRIAL:
Please click here for clinical trial information.
41 articles about Tianjin CanSino Biologics
-
The big Connect in Pharma conference is coming up with digitization and supply chain on the agenda and CanSino Biologics, HUTCHMED and more have positive research news.
-
CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing
5/19/2022
CanSino Biologics Inc. announced that the World Health Organization has granted Emergency Use Listing for Convidecia™, CanSinoBIO's Recombinant Novel Coronavirus Vaccine.
-
CanSinoBIO Rebrands to Reflect Commitment to Life Sciences Research
4/25/2022
CanSino Biologics Inc. announced its new brand identity, which is intended to represent the Company's continuous dedication to life sciences research and its commitment to protecting the global population with innovative, high-quality and accessible vaccines and empowering people to lead a healthy and better life.
-
CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China
4/4/2022
CanSino Biologics Inc. announced that the National Medical Products Administration of China granted approval for the clinical trial application of its COVID-19 mRNA vaccine in China.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
CanSinoBIO's Convidecia™ Approved as Heterologous Booster in Malaysia and Indonesia
3/22/2022
CanSino Biologics Inc. announced that its Recombinant Novel Coronavirus Vaccine has been approved by the Ministry of Health Malaysia and the Indonesian National Agency of Drug and Food Control as a heterologous booster.
-
Latest Study Shows Advantages of CanSinoBIO's Convidecia™ as Heterologous Booster against Omicron Variant
3/14/2022
CanSino Biologics Inc. announced that medRxiv, a preprint platform for preliminary biomedical research, published an academic paper1 on the efficacy of CanSinoBIO's Recombinant COVID-19 Vaccine as a heterologous booster against the Omicron variant.
-
CanSinoBIO's Convidecia™ Approved as Heterologous Booster in China
2/19/2022
CanSino Biologics Inc. announced that its Recombinant Novel Coronavirus Vaccine has been approved by the Joint Prevention and Control Mechanism of the State Council of China as a heterologous booster, making it the first adenovirus-vectored vaccine to be included in the heterologous vaccination program in China.
-
Latest Study Shows Encouraging Results of CanSinoBIO's Inhaled COVID-19 Vaccine as Heterologous Booster
1/11/2022
CanSino Biologics Inc. announced that Preprints with The Lancet, a collaboration between the research sharing platform SSRN and The Lancet, published a clinical study on the safety and immunogenicity of CanSinoBIO's Recombinant COVID-19 Vaccine for Inhalation Convidecia™as a heterologous booster.
-
CanSinoBIO Announces Approval for its MCV4 Product Menhycia™ in China
1/8/2022
CanSino Biologics Inc. announced that the National Medical Products Administration of China granted approval for its ACYW135 Meningococcal Conjugate Vaccine, making it the first of its kind to be authorized in China.
-
Clinical Catch-Up: December 27-31
1/3/2022
Not surprisingly, the week between Christmas and New Year was quiet in terms of clinical trial news. However, there were some announcements. Here’s a look. -
Convidecia™ Phase III Results Published in The Lancet
12/24/2021
CanSino Biologics Inc. today announced that The Lancet[1] published its Phase III clinical trial results on the safety and efficacy of its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) ("Ad5-nCoV", trade name: Convidecia™).
-
The Pfizer-BioNTech vaccine (now Comirnaty®) was fully approved by the U.S. Food and Drug Administration (FDA) on August 23 and boosters of this shot are now available to the most vulnerable Americans.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
CanSinoBIO Receives European GMP Certification for its COVID-19 Vaccine Convidecia™
5/24/2021
CanSino Biologics Inc. announced that its Recombinant Novel Coronavirus Vaccine, has been granted a Good Manufacturing Practice certificate by the Hungarian National Institute of Pharmacy and Nutrition.
-
COVID-19 News: Researchers Discover a New Variant, Antiviral Shows Promise in Hamsters and More
4/20/2021
Please check out the biopharma industry's COVID-19 stories that are trending for April 20, 2021. -
As the U.S. reports surges in COVID-19 infections despite increased enrollment in vaccines, news continues to break about therapies, vaccines, and the risks involved with the new vaccines. Here’s a look.
-
Clinical Catch-Up: February 8-12
2/15/2021
It was a busy week for clinical trial announcements and news. Here’s a look. -
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 17, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 12, 2020.